# Amylyx Pharmaceuticals, Inc. (AMLX) · Edgar & Edgarette company card

> Amylyx Pharmaceuticals (AMLX) saw revenue fall 100% in FY2025 to $0 million, operating margin null against a -3.8% median for pharmaceutical preparations, equity 91.8% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1658551 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/AMLX) · [JSON](https://www.pops4.com/boards/company/AMLX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | -100.0% |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -360.2%) |
| Net margin | -Infinity% |
| Operating cash flow | −$123M |
| Capital spending | $138,000 |
| Free cash flow | −$123M |
| Cash | $227M |
| Long-term debt | — |
| Total assets | $333M |
| Total equity | $305M |
| Equity ÷ assets | 91.8% |
| Return on equity | -47.4% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 7.18 (safe zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative; operating loss: a margin of -Infinity% in FY2025

## Edgarette's reading

Exposure: revenue $0K (FY2025). Experience: revenue down 100.0% on the year; operating margin null, down from -360.2%. Soundness: equity 91.8% of assets, return on equity -47.4%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $0K and $0K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin null against a -3.8% median; growth -100.0% against 13.7%.

Range logged 2026-09-20, receipt 835d4212b884195d, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 8-K · filed 2026-09-08 · 1.01 Entry into a Material Definitive Agreement · [filing](https://www.sec.gov/Archives/edgar/data/1658551/000119312526385331/0001193125-26-385331-index.htm)
- 8-K · filed 2026-08-20 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1658551/000119312526359418/0001193125-26-359418-index.htm)
- 8-K · filed 2026-08-18 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1658551/000119312526354793/0001193125-26-354793-index.htm)
- 8-K · filed 2026-08-18 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1658551/000119312526354716/0001193125-26-354716-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1658551/000119312526336682/0001193125-26-336682-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1658551/000119312526336670/0001193125-26-336670-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001658551.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1658551

## Cite

POPS4, Edgar & Edgarette: Amylyx Pharmaceuticals, Inc. (AMLX) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/AMLX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.